From the Journals

Low plasma sodium predicts complications in SCD acute pain episodes


 

FROM THE AMERICAN JOURNAL OF MEDICINE

Hyponatremia, defined as a plasma sodium concentration ≤ 135 mmol/L at admission, was associated with complications during episodes of acute pain from sickle cell disease, according to a large retrospective analysis.

The French study assessed 1,218 stays of 406 patients admitted for treatment of an acute painful episode of sickle cell disease between 2010-2015. The primary composite endpoint comprised acute chest syndrome, intensive care unit transfer, red blood cell transfusion or inpatient death. The analyses were adjusted for age, sex, hemoglobin genotype and concentration, LDH concentration, and white blood cell count, according to the researchers.

Hyponatremia at admission in the center was associated with the primary endpoint (adjusted odds ratio (OR) 1.95, P = .001). This association was independent from baseline demographic characteristics (age, sex, hemoglobin genotype) and from other prognostic factors examined in the study (lower hemoglobin concentration, higher white blood cell count and LDH concentration).

With regard to individual components of the primary endpoint, hyponatremia was associated with acute chest syndrome (OR 1.95, P = .008) and red blood cell transfusion (OR 2.71, P <.001), but not significantly with intensive care unit transfer (OR 1.83, P = .074). In addition, the adjusted mean length of stay was significantly longer by 1.1 days ( P < .001) in patients with hyponatremia at admission.

The study received no funding and the researchers reported that they had no conflicts of interest.

SOURCE: Rech JS et al. Amer J Med. 2020. doi.org/10.1016/j.amjmed.2020.02.017.

Recommended Reading

ASH releases guidelines on managing cardiopulmonary and kidney disease in SCD
MDedge Hematology and Oncology
BCL11A-directed gene therapy advances in sickle cell disease
MDedge Hematology and Oncology
The evolving landscape of complement inhibition therapy
MDedge Hematology and Oncology
Sevuparin failed for acute VOC in sickle cell, but may have preventive potential
MDedge Hematology and Oncology
Deferiprone noninferior to deferoxamine for iron overload in SCD, rare anemias
MDedge Hematology and Oncology
Flow-mediated dilation of brachial artery predicts renal dysfunction in sickle cell disease
MDedge Hematology and Oncology
Genetic testing helps avoid false hemoglobinopathy diagnoses in newborns
MDedge Hematology and Oncology
Chimerism and the use of fludarabine associated with secondary graft failure in aplastic anemia
MDedge Hematology and Oncology
Sickle cell patients with vitamin D deficiency prone to more ED visits, longer stays
MDedge Hematology and Oncology
New sickle cell drugs give hope, but access remains a barrier
MDedge Hematology and Oncology